The Texas Medical Center Library

DigitalCommons@TMC
The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses
(Open Access)

The University of Texas MD Anderson Cancer
Center UTHealth Graduate School of
Biomedical Sciences

5-2020

Frequency of copy number variants involving the sex
chromosomes in a clinical setting
Autumn Vara

Follow this and additional works at: https://digitalcommons.library.tmc.edu/utgsbs_dissertations
Part of the Medical Genetics Commons

Recommended Citation
Vara, Autumn, "Frequency of copy number variants involving the sex chromosomes in a clinical setting"
(2020). The University of Texas MD Anderson Cancer Center UTHealth Graduate School of Biomedical
Sciences Dissertations and Theses (Open Access). 1009.
https://digitalcommons.library.tmc.edu/utgsbs_dissertations/1009

This Thesis (MS) is brought to you for free and open
access by the The University of Texas MD Anderson
Cancer Center UTHealth Graduate School of Biomedical
Sciences at DigitalCommons@TMC. It has been
accepted for inclusion in The University of Texas MD
Anderson Cancer Center UTHealth Graduate School of
Biomedical Sciences Dissertations and Theses (Open
Access) by an authorized administrator of
DigitalCommons@TMC. For more information, please
contact digitalcommons@library.tmc.edu.

FREQUENCY OF COPY NUMBER VARIANTS INVOLVING THE SEX CHROMOSOMES
IN A CLINICAL SETTING
By
Autumn Elizabeth Vara, B.S.

APPROVED:

______________________________
David Rodriguez-Buritica, M.D.
Advisory Professor

______________________________
Syed S. Hashmi, M.D., MPH, Ph.D

______________________________
Janice L. Smith, Ph.D

______________________________
Victoria F. Wagner, M.S.

_____________________________
Kathryn Gunther, M.S.

APPROVED:

____________________________
Dean, The University of Texas
MD Anderson Cancer Center UTHealth
Graduate School of Biomedical Sciences

FREQUENCY OF COPY NUMBER VARIANTS INVOLVING THE SEX
CHROMOSOMES IN A CLINICAL SETTING

A
THESIS
Presented to the Faculty of
The University of Texas
MD Anderson Cancer Center UTHealth
Graduate School of Biomedical Sciences
in Partial Fulfillment of
the Requirements for the
Degree of
MASTER OF SCIENCE

by
Autumn Elizabeth Vara, B.S.
Houston, Texas
May 2020

iii
FREQUENCY OF COPY NUMBER VARIANTS INVOLVING THE SEX
CHROMOSOMES IN A CLINICAL SETTING

Autumn Elizabeth Vara, B.S.

Advisory Professor: David F. Rodriguez-Buritica, M.D.

Abstract
Copy number variants (CNVs) are a common finding in the clinical setting and contribute
to both genetic variation as well as disease. Recently, studies have described the accumulation
of multiple CNVs as a disease modifying mechanism. While it has been characterized how
additional CNVs may play a role in phenotype, in which ways and to what extent sex
chromosomes are involved has not been fully described. We performed a secondary data analysis
using the DECIPHER database on 2,273 de-identified individuals with 2 CNVs. CNVs were
designated primary and secondary based on our criteria and characteristics of both CNV groups
were described. Further analysis was performed identifying differences in CNVs on the sex
chromosomes vs autosomes. We found that CNVs on the sex chromosome have a significant
difference compared to autosomes when comparing median size (p=0.013), pathogenicity
classifications (p<0.001), and variant classification (p=0.001). We identified chromosome
combinations for primary and secondary CNVs, and identified the X chromosome was the most
common site for a secondary CNV. Additionally, we observed the plurality of secondary CNVs
fell in the same chromosome as the primary CNV. From this study, we can conclude that the X
chromosome is the most common site for secondary CNVs in a clinical setting. Identification of
chromosome combinations for primary and secondary CNVs is essential in explanation of
complex phenotypes and highlights areas of importance of the human genome.
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Introduction
Copy number variants (CNVs) are structural changes of the human genome due
to chromosomal anomalies such as deletions, duplications or insertions. (Girirajan,
Campbell, and Eichler 2011). CNVs have been well described as contributing to genetic
variability as well as disease (Nowakowska 2017). These segments of DNA are found in
all individuals and include deleted and duplicated regions ranging from one kilobase pair
(kbp) to several megabase pairs (Mbp) (Itsara et al. 2009). CNVs in the human genome
often arise in regions containing low copy repeats or segmental duplications, which are
blocks of DNA that share >90% sequence identity (Tie-Lin Yang 2018). The most
common mechanism from which this occurs is non-allelic homologous recombination
(NAHR) and often is responsible for recurrent CNVs in the genome (Hastings et al.
2009). We can predict that with the greater the density of segmental duplications in a
chromosome, the more enriched that chromosome may be for CNVs. Another
mechanism associated with CNVs, and thought to be responsible for non-recurrent
CNVs, is that of non-homologous end joining (Tie-Lin Yang 2018).
It is estimated that on average, a healthy individual harbors approximately 3-7
CNVs with a total average of 540 kbp of copy number variable DNA per person (Itsara
et al. 2009). The majority of copy number variants less than ~400 kbp are thought to be
benign although exceptions for smaller, pathogenic CNVs exist. (Miller et al. 2010). For
instance, 5-10% of healthy individuals have one CNV spanning at least 500 kbp
suggesting that size does not always correlate to pathogenicity (Itsara et al. 2009).
Certain rare, pathogenic CNVs have been identified in individuals with a
characteristic set of clinical features and contribute to syndromic disorders such as
Williams syndrome and 22q11.2 deletion syndrome. More recently, rare, recurrent
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CNV’s in conjunction with a secondary hit, such as an additional CNV, were found to
exacerbate phenotype (Girirajan et al. 2012). A recurrent microdeletion at 16p12.1 is
associated with variable expressivity for a spectrum of conditions including
neuropsychiatric disorders, autism spectrum disorder, and intellectual disability when in
conjunction with other CNVs (Girirajan et al. 2010) To better understand this
phenomenon Girirajan et al. conducted a study which looked at 32,587 chromosomal
microarrays from children with intellectual disability with or without congenital
anomalies and compared that with 8,329 control samples. In this analysis, 10.1% of
patients with a rare CNV known to be associated with a neurodevelopmental phenotype
or disorder had at least one additional CNV larger than 500 kbp on an autosome, further
characterizing the compounding effect that additional CNVs have on disease severity.
Other studies also describe a similar observation that a “second” hit, such as a CNV,
exacerbates phenotypes (Girirajan et al. 2010, Le Gall et al. 2017). Prakash et al.
identified a subset of females with Turner syndrome (TS) with a secondary event, such
as a CNV, are significantly more likely to have congenital heart disease than females
with TS who did not (Prakash et al. 2016)
While these studies better characterize how additional CNVs may play a role in
driving phenotypic expression, how and to what extent sex chromosomes are involved
has not been fully described. Sex chromosome aneuploidies are more common than
aneuploidies involving the autosomes in, both, neonates and miscarriages, which may
support the idea that CNVs involving the sex chromosomes are more common than
those on autosomes (Templado, Uroz, and Estop 2013). Based on this information, it is
our hypothesis that sex chromosomes will more commonly harbor additional CNVs than
autosomes. Although there is no current data supporting this hypothesis, our institution
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has identified several individuals found to harbor pathogenic CNVs contributing to the
phenotype, in addition to a secondary sex chromosome abnormality. This novel research
has the potential to add knowledge in highlighting sex chromosomes in etiology of
indications, genomic regions that are of importance, and provide clues for predicting
clinical phenotypes.
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Methods:
Study sample
This project involves secondary data analysis on a de-identified dataset from
DECIPHER (https://decipher.sanger.ac.uk/), a publicly available database in which
referring clinicians submit genotypic and phenotypic information on patients who have
consented for broad data-sharing. DECIPHER is comprised of data independently
submitted by an affiliated institution and at minimum includes chromosome(s) involved,
start and end breakpoints for each CNV, and variant class (duplication, deletion, etc.) for
each individual. Information such as pathogenicity, inheritance pattern, phenotype, mean
ratio, and contribution to phenotype was also available if provided by the referring
clinician. Information pertinent to this study include chromosome involved, start/end
point, variant class, pathogenicity, inheritance pattern, and phenotype. The dataset
received encompasses submissions since the creation of DECIPHER in 2004 until May
2019.
For variants where pathogenicity was provided, DECIPHER categorized into
five classes labeled as ‘pathogenic’, ‘likely pathogenic’, ‘variant of uncertain
significance (VUS)’, ‘benign’, or ‘likely benign’. We kept these classifications as is with
the exception of ‘benign’ and ‘likely benign’ which were combined into one category
defined as ‘benign’.
Inheritance patterns for CNVs provided by DECIPHER fell into multiple
categories. Variants defined as ‘de novo constitutive’ or ‘de novo mosaic’ in the
DECIPHER database were combined and categorized as ‘de novo’ for the purpose of the
analysis. Variants in DECIPHER designated ‘biparental’, ‘inherited from normal

5

parent’, ‘inherited from a parent with similar phenotype to child’, ‘inherited from a
parent with unknown phenotype’, ‘maternally inherited, constitutive in mother’,
‘maternally inherited, mosaic in mother’, ‘paternally inherited, constitutive in father’ or
‘paternally inherited, mosaic in father’ were further combined into ‘inherited’. These
two categories were reserved for all studies regarding inheritance.
The size of each CNV was calculated using the provided start and break point for
each CNV.
Variants received from DECIPHER were categorized into variant classes labeled
‘gain’, ‘triplication’, ‘duplication’, ‘duplication/triplication’, ‘amplification’, or
‘deletion’. CNVs labeled as ‘duplication/triplication’ or ‘gain’ were excluded due to
ambiguity (n=5).
Inclusion/Exclusion criteria
A total of 24,525 unique patients were received from DECIPHER database. For
the purpose of this study, patients with strictly one copy number variant were excluded
for analysis (n=19,031). Patients were further eliminated if break points were indicative
of terminal CNVs that suggested an unbalanced translocation inherited from a balanced
carrier parent (n=160). Patient sex was then manually extracted from DECIPHER for
this subset of patients using the patient ID provided. Patients with unknown sex were
eliminated from the dataset, reaching a final sample of 4,263 unique individuals.
For studies describing the characteristics of secondary CNVs, only individuals
with 2 CNVs were analyzed. Therefore, an additional 867 individuals were excluded due
to harboring > 3 CNVs. For the remaining 3,396 individuals, it was necessitated that one
CNV be equal to or larger than 500 kbp. This was designated the primary CNV for all
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individuals. The secondary CNV was thus defined as the smaller of the two variants.
There were 961 individuals who did not have a CNV > 500 kbp. Seven patients were
further excluded due to harboring 2 CNVs with the exact size on the same chromosome,
therefore we could not determine which would be defined as the primary and secondary
CNVs. Additionally, individuals were eliminated if two CNVs were found on the same
chromosome less than 300 kbp apart to reduce the possibility of being one large CNV.
There is no current literature to suggest how far 2 CNVs on the same chromosome
should be to exclude this likelihood, thus 300 kbp was chosen arbitrarily. We also
disregarded patients with 2 CNVs that embedded or overlapped one another. This gave a
final sample size of 2, 273.
Studies performed on each cohort
For the full cohort of 4,263 individuals, descriptive studies describing number of
CNVs (Table 1), sex (Table 2), pathogenicity, inheritance pattern, size of CNV, variant
class, and chromosome frequencies were performed. There were 4,912 CNVs with
known pathogenicity (Figure 1). Inheritance pattern was known for 3,489 CNVs (Figure
2). Variant classes were compared to pathogenicity classifications for 4,912 CNVs
(Figure 3). Median sizes of CNVs were compared to pathogenicity groups. To determine
chromosome involvement, we created a graph comparing each chromosome and the
frequency of CNVs that were found on the respective chromosome (Figure 4a). We
compared frequency of CNVs per chromosome to chromosome length to determine if
size was a contributing factor to CNV density (Figure 4b).
To highlight characteristics of secondary CNVs, we described sex, pathogenicity,
inheritance pattern, size, variant classification, and chromosome involvement in this
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cohort (n=2,273). Pathogenicity was known for 990 primary and1,136 secondary CNVs
(Figure 5). Inheritance patterns were known for 1,007 primary CNVs and 851 secondary
CNVs. Variant classification was compared between primary and secondary CNVs.
Additionally, we compared variant classes and pathogenicity categories for both,
primary and secondary CNVs. Chromosome involvement for primary and secondary
CNVs are compared Figure 6. A heatmap was then created to identify combinations of
chromosome involvement for primary and secondary CNVs (Figure 7a). We then
recreated this map to highlight which chromosomes were frequent sites of secondary
CNVs (7b). To do this, we calculated the average relative frequency of each secondary
CNV. The y-axis was then reorganized from chromosome with the highest relative
frequency to the lowest.
To characterize CNVs involving the sex chromosomes, we used the previous
sample of 2,273 with 2 CNVs. There were 438 CNVs harbored on the sex chromosomes.
Of these CNVs, 205 were classified as primary and 233 were secondary variants.
Comparisons were made between location of CNV (sex chromosomes vs autosomes)
and size, pathogenicity, and variant classes. Pathogenicity groups are compared between
location of CNV (Figure 8). We looked to identify if there were pairs of pathogenicity
combinations for primary and secondary CNVs that were recurrent. To perform this,
separate investigations were completed based on if the primary CNV fell on an
autosome or sex chromosome. For this analysis we focused on individuals with 46,XX
karyotype to control for chromosome dosage and size (Figure 9). Variant classes were
compared between location of CNV. Further analysis was performed to identify pairs of
variant class combinations. Separate investigations were performed based on if the
primary CNV fell on an autosomes vs sex chromosome. For this part of the analysis, we
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focused again on individuals with 46, XX karyotype to control from chromosome
dosage and size. Additionally, we combined variant classes of ‘duplication’ and
‘triplication’ into a single category labeled as ‘gain’ (Figure 10). We further investigated
secondary CNV characteristics of individuals who had a pathogenic CNV on the Xchromosome to identify any trends. We looked to identify any recurrent common
secondary CNV, variant class, and phenotype. We limited this study again to
individuals with 46,XX karyotype (Table 3).
Statistical analysis
All analyses were performed in STATA (v.13.1). P-value <0.05 was set for
statistical significance. Continuous variables were not normally distributed and were
described using medians and interquartile ranges (IQR). A Kruskal-Wallis test was used
to compare continuous variables with categorical. A post-hoc Dunn test was performed
to characterize results with statistical significance. Chi-squared tests were used to
compare categorical variables.
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Results
Full cohort characteristics
There were 4,263 unique individuals from the DECIPHER cohort who had more
than one CNV. The number of CNVs per individual ranged anywhere from 2-13 with
the majority of individuals (79.7%) having only two (Table 1). Among this sample there
were a total of 9,766 CNVs.
Number
n
%
of
CNVs
2
3,399
79.7
3
624
14.6
4
171
4.0
5
40
0.9
6
12
0.3
7
8
0.2
8
4
0.2
9
2
0.1
10
2
0.1
11
0
0
12
0
0
13
1
0.1
Table 1. Frequency of number of CNVs. This table categorizes percentages based on
number of CNVs identified in individuals with 2 or more CNVs.

We did find an enrichment for males to harbor more than one CNV in this
cohort. The majority of individuals (58%) had a normal male karyotype of 46,XY and
41% had a normal female karyotype of 46,XX. There were 13 individuals (0.3%) with
sex chromosome aneuploidies including 45,X; 47,XXX; 47,XXY; and 47,XYY (Table
2).
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Sex
n
%
45,X
2 0.05
47,XXX
1 0.02
47,XXY
4 0.09
47,XYY
6 0.14
46,XX
1,759 41.26
46,XY
2,491 58.43
Table 2. Frequency of sex chromosomal aneuploidies. Represented in this table are
the karyotypes observed in individuals with two or more CNVs and the respective
frequency.

Due to the nature of the dataset used, half of the CNVs did not have
pathogenicity information included as they were not submitted by the referring center
and therefore listed as unknown. For 4,912 variants where pathogenicity was known, the
largest category was VUS at 44% (Figure 1).

Pathogenicity

21%
44%
19%
16%

Benign

Likely pathogenic

Pathogenic

Uncertain

Figure 1. Pathogenicity of CNVs in individuals with >2 CNVs. This figure represents
the percentage make up of pathogenicity classification for 4,912 CNVs in this cohort.

6,277 variants (67%) did not have inheritance data provided. Of the 3,489 variants with
inheritance information, there was a nearly equal distribution with 51% of variants
classified as de novo and 49% inherited (Figure 2).
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Inheritance Pattern

49%

51%

De novo

Inherited

Figure 2. Inheritance patterns of CNVs in individuals with >2 CNVs. De novo vs
inherited variants in 3,489 CNVs.
There was a statistically significant difference in median sizes amongst
pathogenicity groups (p<0.001). CNVs defined as pathogenic had the largest median
size of approximately 3.2 Mbp with an interquartile range (IQR) of 7.3 Mbp (8.5 Mbp1.2 Mbp). The smallest pathogenic variant measured less than 0.001 Mbp (60 base
pairs). The largest pathogenic variant was approximately 155 Mbp which is consistent
with a sex chromosome aneuploidy of the X chromosome. Variants denoted LP had a
median size of approximately 0.6 Mbp and IQR of 1.6 Mbp (1.9 Mbp-0.3 Mbp). The
smallest LP CNV was less than 0.001 Mbp (97 base pairs) while the largest was 60
Mbp. Benign variants had the smallest median size of the groups with a median of 0.1
Mbp with an IQR of 0.2 Mbp (0.3 Mbp-0.07 Mbp). The smallest benign variant was less
than 0.001 Mbp (36 base pairs) and the largest 100 Mbp. VUS CNVs had a median
value which fell between those of LP and benign at approximately 0.4 Mbp and an IQR
of 0.5 Mbp (0.7 Mbp-0.2 Mbp). We identified a significantly larger median of
pathogenic CNVs compared to all other categories (p<0.001). LP variants had a
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significant larger median than VUS and benign (p-<0.001). VUS had a significantly
larger median than benign (p<0.001).
Variant classes were compared to pathogenicity classifications and a statistically
significant difference was observed (p<0.001). Over 60% of pathogenic variants were
found to be deletions. Reciprocally, 55% of benign variants and 61% of VUS were
defined as duplications (Figure 3).

Pathogenicity group

Makeup of variant classes based on pathogenicity
Benign/likely benign
VUS
Likely pathogenic
Pathogenic
0

10

20

30

40

50

60

70

Percentage
Triplication

Duplication

Deletion

Amplification

Figure 3. Frequency of CNVs per variant class based on pathogenicity. Percentages
that made up each variant class for each pathogenicity group in individuals with two or
more CNVs.

Of the 9,766 CNVs, nearly 11% were found between the two sex chromosomes,
with 9.4% located on the X chromosome and 1.5% on the Y chromosome. Other
chromosomes enriched for CNVs include 1, 16, 15, and 2, each approximately
representing 7% of CNVs, respectively (Figure 4a). Chromosome 21 had the smallest
amount of CNVs of all the chromosomes. We also identify that chromosomes 22, 16,
and 15 have an enriched amount of CNVs per Mbp, whereas chromosome 5 has the least
(Figure 4b).
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A. Chromosome involvement of CNVs in those with >2
1000
900
800
700
600
500
400
300
200
100
0
1

2

3

4

5

6

7

8

9

10 11 12 13 14 15 16 17 18 19 20 21 22 X
CHROMOSOME

Y

B. Frequency of CNVs as function of chromosome length
(Mbp)
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9
8
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3
2
1
0
1

2

3
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7
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9

10 11 12 13 14 15 16 17 18 19 20 21 22 23 24
CHROMOSOME

Figure 4. Chromosome involvement of CNVs in those with >2 CNVs. Panel A
characterizes the frequency of CNVs in individual chromosomes for individuals who
have two or more copy number variants. The x-axis lists each chromosome and the yaxis shows the number of CNVs. Panel B illustrates the number of CNVs per Mbp for
each chromosome.

Characteristics of secondary CNVs
When further characterizing secondary CNVs, there were 2,273 unique
individuals who exclusively had two CNVs on different chromosomes or on same
chromosomes with more than 300 kbp apart, with one of the CNVs’ size equal to or
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large than 500 kbp. Of the 2,273 individuals, 1,269 (56%) had a 46,XY karyotype, and
996 (44%) had a 46,XX karyotype. There were 8 additional patients (less than 1%) with
the same sex chromosome aneuploidies as described previously.
We observed a statistically significant difference in pathogenicity classification
between the primary and secondary CNVs (p<0.001). 1,283 individuals (53%) did not
have pathogenicity information for the primary CNV. Of the primary CNVs for which
pathogenicity classification was known, 33% were labeled as pathogenic, 27% LP, 4%
benign, and 36% were VUS. The same analysis was performed on secondary CNVs.
1,136 individuals (51%) had known data regarding the pathogenicity of the secondary
CNV. Similarly to primary CNVs, the greatest proportion of variants was classified as
VUS (46%). Pathogenic and LP variants were found in a smaller proportion at 15% and
22% respectively. Benign variants made up 16% of secondary CNVs. Comparisons of
primary and secondary CNV pathogenicity can be seen in Figure 5.
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A

Pathogenicity of primary CNVs
4%

.

27%

36%

33%
Benigh/Likely benign

B

Likely pathogenic

Pathogenic

Uncertain

Pathogenicity of secondary
CNVs

.
16%

47%
22%

15%
Benign/Likely benign

Likely pathogenic

Pathogenic

Uncertain

Figure 5. Pathogenicity of primary and secondary CNVs. Panel A illustrates the
distribution of pathogenicity classes in primary CNVs. Panel B highlights the
pathogenicity classification of secondary CNVs.

Inheritance patterns were compared between primary and secondary CNVs and a
statistically significant difference was observed (p<0.001). For the primary CNVs, 1,266
individuals (56%) had unknown or missing inheritance data. Of those CNVs where
inheritance pattern was provided, 68% of variants were de novo whereas 32% were
inherited. This demonstrates that primary CNVs were largely de novo. Then shifting to
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secondary CNVs, there were 851 individuals (37%) with known inheritance in this
group. We observed 52% of variants classified as de novo and 48% inherited.
The median sizes for each CNV were further analyzed and a statistically
significant difference was observed between primary and secondary CNVs (p<0.001).
Focusing on primary CNVs, the median size was approximately 2.0 Mbp. The smallest
variant in this category was just over 0.5 Mbp and the largest was 155 Mbp. Again, the
largest CNV consistent with a sex chromosome aneuploidy of the X chromosome. There
was an IQR of approximately 5 Mbp (6.3 Mbp-0.99 Mbp). Median sizes were
investigated for each pathogenicity group. Pathogenic primary CNVs had a median size
of 4.7 Mbp, LP variants were approximately 1.6 Mbp, VUS had a median size of 1.1
Mbp, and benign CNVs were 0.8 Mbp. The median size for secondary CNVs was
smaller than primary CNVs by approximately 1.7 Mbp, with a median size 0.4 Mbp.
The smallest variant was just 11 base pairs while the largest was 89 Mbp. There was an
IQR of approximately 1 Mbp (1.3 Mbp-0.2 Mbp). Pathogenic variants had a median size
of 1.7 Mbp, LP variants were approximately 0.5 Mbp, VUS had a median of 0.3 Mbp,
and 0.16 Mbp for benign CNVs.
We compared variant classes between primary and secondary CNVs and did not
observe a statistically significant difference in classification of variants between the
groups (p=0.093). Primary CNVs were comprised of 45% deletions and 52%
duplications. Secondary CNVs were made up of 48% deletions and 51% duplications.
3% and 1% of primary CNVs and secondary CNVs were composed of triplications,
respectively. We then compared variant classes and pathogenicity categories for both,
primary and secondary CNVs. 1,145 primary CNVs were analyzed and a statistically
significant difference (p<0.001) was observed between variant class and pathogenicity.
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85% of benign variants and roughly 60% of VUS’s were classified as duplications while
62% of pathogenic variants were classified as deletions. A similar analysis was
performed for 1,136 secondary CNVs and similarly a statistically significant difference
was observed between variant classes and pathogenicity categories (p=0.003). Parallel to
primary CNVs, 60% of pathogenic variants were deletions. Interestingly, 53% of likely
pathogenic variants were classified as duplications while 46% were deletions. Benign
variants made up 53% of duplications and 44% of deletions.
No significant difference was identified between the chromosome involvement
of primary and secondary CNVs (p=0.070). For both primary and secondary CNVs, the
most common chromosome to harbor a CNV was the X chromosome making up 7.6%
and 8.9% of CNVs, respectively (Figure 6).

Chromosome involvement
250

Frequnecy

200
150
100
50
0
1

2

3

4

5

6

7

8

9

10 11 12 13 14 15 16 17 18 19 20 21 22 X

Chromosome
Primary CNV

Secondary CNV

Figure 6. Chromosome involvement in primary and secondary CNVs. This figure
compares the frequency of chromosome involvement for primary and secondary CNVs.
The chromosome is listed on the x-axis, and the number of CNVs seen is labeled on the
y-axis.

Y
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We created a map to identify recurrent combinations of chromosome
involvement for primary and secondary CNVs (Figure 7a). Diagonally, we are observing
a trend that secondary CNVs commonly fall in the same chromosome as the primary
CNV. There is evident enrichment of secondary CNVs in chromosomes 15, 16, and the
X chromosome. Marked recurrent chromosome combinations involving primary CNVs
on an autosome include chromosomes 4/8, 12/2, and 20/4. The X chromosome has a
noticeable pattern as common site for secondary CNV when the primary CNV is on
chromosomes 3, 12, 16, and Y. When this map was recreated with the y-axis in
descending order of relative frequency, we highlight the most common chromosomes for
a secondary CNV to occur (7b). Although the Y chromosome is not highly involved in
CNVs, we are observing a high combination of Y chromosome being involved in a
secondary CNV, when the primary is also on the Y chromosome.
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A

B

Figure 7. Chromosome combinations of primary and secondary CNVs for
individuals. Chromosomes of the primary CNV are found along the top x-axis while
secondary CNV chromosomes run along the y axis. The numbers inside boxes represent
percentages of column totals. The color of the boxes intensity as the frequency of a
chromosome pair increases. In panel A, the secondary CNV chromosomes are listed in
numerical order. In panel B, the y-axis is arranged by average relative frequency of
secondary CNVs, highlighting which chromosomes averaged more secondary CNVs.
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Characterization of CNVs involving the sex chromosomes
We identified a significant difference between the median sizes of CNVs
involving the autosomes and sex chromosomes (p=0.013). CNVs on the autosome had a
larger median size than those on the sex chromosomes (p=0.0067). Next, the median
sizes for primary CNVs were compared based on location of CNV (sex chromosome or
autosome). We found no statistical difference in median sizes between the two
(p=0.479). A primary CNV located on a sex chromosome was roughly 1.9 Mbp whereas
primary CNV on an autosome was approximately 2.0 Mbp. A similar analysis was
performed for secondary CNV and we identified a statistically significant difference in
median sizes for secondary CNVs (p=0.029). Secondary CNVs had a larger median if
found on an autosome (p=0.0104). The median size was 0.35 Mbp on the sex
chromosomes. In contrast, the median sizes of secondary CNVs located on an autosome
found the median size to be 0.44 Mbp.
We observed a statistically significant difference when comparing pathogenicity
groups and location of CNV (p<0.001). VUS made up the largest percentage of
pathogenicity groups for both autosomes and sex chromosomes, however makes up a
greater proportion of CNVs on the sex chromosomes (Figure 8). CNVs on autosomes
had a greater percentage of pathogenic/LP, while we see a slightly higher number of
benign variants in sex chromosomes.
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Pathogenicity of sex chromosome vs autosome
CNVs
60
50
40
30
20
10
0
Pathogenic

LP
Autosome

VUS

Benign

Sex chromosome

Figure 8. Comparison of pathogenicity groups for sex chromosomes and autosomes.
Percentages of CNV pathogenicity classifications for sex chromosomes and autosomes.
The x-axis represents the pathogenicity group while the y-axis represents the percentage
of CNVs seen.

We also observed a statistical significance between pathogenicity and location of
CNV for primary CNVs (p=0.015). There were 90 primary CNVs on the sex
chromosomes that had pathogenicity information provided. 49% of those CNVs were
classified as VUS. Breakdowns of other pathogenicity classifications include: 23%
considered pathogenic, 20% LP, and 8% benign. We then compared this to 990 primary
CNVs on the autosomes where 36% were classified as VUS, 34% pathogenic, 27% LP,
and 3% benign. A similar analysis was performed for secondary CNVs. A statistical
significance was again observed (p=0.003). There were 104 individuals with a
secondary CNV with known pathogenicity on the sex chromosomes. Of this cohort, the
majority (62%) had CNVs classified as VUS. Pathogenic variants made up 9% of the
group, LP 10% and benign CNVs contributed 19%. We then compared this with 969
individuals who had a secondary CNV on an autosome where 46% were classified as
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VUS, and 15%, 17%, and 22% made up the pathogenic, benign, and likely pathogenic
groups, respectively.
When analyzing pathogenicity combinations, there were 412 females with a
primary CNV on an autosome. The most frequent combination seen was a primary CNV
classified as a VUS with a secondary CNV of the same classification (Figure 9a). The
same analysis was performed for 43 individuals whose primary CNV fell on the X
chromosome. Similarly to the previous analysis, the most frequent combination was
having 2 CNVs which were both classified as VUS (Figure 9b).
A.

Secondary
CNV
classification

Primary CNV on autosome pathogenicity
classification

Pathogenic
LP
VUS
Benign

B.

Pathogenic
53
28
45
32

LP
3
54
36
6

VUS
12
11
93
29

Benign
1
5
1
3

Secondary
CNV
classification

Primary CNV on X chromosome
pathogenicity classification
Pathogenic
LP
VUS
Benign

Pathogenic
6
0
3

LP
2
2
2

VUS
2
2
17

Benign
1
0
0

1

0

4

1

Figure 9. Frequency of pathogenicity combinations for individuals with 2 CNVs.
Panel A represents combinations when the primary CNV falls on an autosome. Panel B
represent when the primary CNV falls on the X chromosome. The number of individuals
observed are represented in the boxes.

A statistical significance of p<0.001 was observed between variant class and
location of CNV. We then compared variant classes of primary CNVs to identify if there
were differences in class based on location of CNV. A statistically significant difference
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was observed (p=0.001). For primary CNVs which fell on a sex chromosome, 65% of
CNVs were classified as duplications and 33% were deletions. Comparing this to 2,075
primary CNVs located on the autosomes where a more equal distribution of 51%
classified as duplications and 47% deletions was identified. 3% of autosomal primary
CNVs were categorized as triplications, and 1% of sex chromosome CNVs. Similarly, a
statistical significance was observed (p<0.001) in variant classification of secondary
CNVs and location of CNV. The majority (73%) of secondary CNVs on the sex
chromosomes were classified as duplications with 25% being labeled as deletions,
whereas autosomes harboring a secondary CNV had a more equal distribution of 48%
duplications and 50% deletions.
When analyzing variant class combinations, there were 89 females who had a
primary CNV on the sex chromosome and 907 individuals with a primary CNV on an
autosome, for which variant classifications were known for both CNVs. We observed
that regardless of where the primary CNV lies, approximately 1/3 of females in each
group harbored a primary CNV classified as gain and secondary CNV classified as a
loss (Figure 10).
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A . P R I M A RY C N V O N A U T O S O M E

204
277

Loss

Secondary CNV

Gain

238
197

Gain

Loss

Primary CNV

Gain
Loss

Secondary CNV

B . P R I M A RY C N V O N X C H R O M O S O M E

26

21

12

30

Loss

Gain

Primary CNV

Figure 10. Variant class combinations. The variant class of the primary CNV is
located on the x-axis with the secondary CNV on the y-axis. The number of times a
specific combination was observed is listed within the bubble. The area of the bubble
increases as the observed frequency increases. Panel A represents the combinations of
variant class when the primary CNV falls on an autosome. Panel B represents the
combinations of variant class when the primary CNV falls on the X chromosome.

Pathogenic X chromosome CNV
There were 12 females who had a pathogenic, primary CNV on the X
chromosome. Ten of the 12 individuals had a primary CNV classified as a deletion. For

25

secondary CNVs, seven individuals had duplications and 5 had deletions. We identified
that half of the secondary variants were defined as pathogenic while just 5 CNVs were
larger than 0.5 Mbp. Six individuals had a phenotype ranging in severity of intellectual
disability (ID).
Phenotype

ID

Size of
primary
CNV

Primary
CNV
variant
class

Chromosome
of secondary
CNV

Size of
secondary
CNV

Variant
class of
secondary
CNV

Pathogenicity
of secondary
CNV

1 155 Mbp
2 1.5 Mbp

Deletion
Deletion

13 18 Mbp
22 1.3 Mbp

Deletion
Pathogenic
Duplication Pathogenic

3 7.2 Mbp

Deletion

15 0.3 Mbp

Deletion

Pathogenic

4 17.8 Mbp

Duplication

3 5.9 Mbp

Deletion

Pathogenic

5 15.7 Mbp

Deletion

6 83 Mbp

Duplication

7 6.6 Mbp
8 155 Mbp

Deletion
Deletion

9 9.9 Mbp
0.023
19 Mbp
0.007
X Mbp
2 0.07 Mbp

Duplication Pathogenic

9 5.6 Mbp

Deletion

16 4.9 Mbp

Duplication Pathogenic

10 2.3 Mbp

Deletion

1 0.47 Mbp

Duplication VUS

11 1.7 Mbp
12 10 Mbp

Deletion
Deletion

X 0.5 Mbp
1 0.31 Mbp

Duplication VUS
Duplication VUS

Deletion

Skeletal
abnormalities,
short stature,
learning
disability
Moderate ID
Absent speech,
ataxia, severe
ID
IUGR,
micrognathia
IUGR,
micrognathia,
cleft palate
Short stature

Benign

Duplication Benign
Deletion
VUS

Abnormality of
the face
Unknown
Cognitive
impairment,
global DD
Mild ID, Short
stature, skeletal
abnormality
ID, obesity,
disproportionate
short-limb
stature
Unknown

Table 3. Characteristics of secondary CNVs for primary X chromosome CNV. This
table characterizes the secondary CNVs seen in 12 females with a pathogenic, primary
CNV on the X-chromosome.
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Of the 8 individuals with sex chromosome abnormalities (SCA) in our cohort, 5
had phenotypic information provided. Two patients fit the phenotype we would expect
with SCA presenting previously described features of developmental delay, delayed
speech, and hypotonia (Wattendorf and Muenke 2005, Tartaglia et al. 2010, Bardsley et
al. 2013). The phenotype of an individual with 47,XXX (Triple X syndrome) was
described as having seizures, severe ID, and tongue thrusting. It has not been previously
reported that individuals with Triple X syndrome present with the above phenotype and
is likely that the secondary CNV classified as a chromosome 4 duplication is causative
of this presentation (Otter, Schrander-Stumpel, and Curfs 2010). Another individual with
a SCA of 47,XYY was reported to have features uncommon of this condition including
abnormalities of the face and skeletal system, microcephaly, and patent ductus arteriosus
(Bardsley et al. 2013). Lastly, a male with 47, XXY was described as having
dysmorphic features of low-set ears and clubbing of toes which has not previously been
reported as a common characteristic.
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Discussion
In an attempt to better characterize secondary CNVs involving the sex
chromosomes, we described a large dataset of patients with two or more CNVs. Our
analysis greatly focused on those with strictly two CNVs where at least one variant was
greater than or equal to 500 kbp. Observation in the clinical setting and frequency of sex
chromosome aneuploidies in live births, we hypothesized that secondary CNVs would
most frequently involve a sex chromosome. We found that 9.2% of this cohort had a
second variant in addition to a primary CNV. Our study demonstrates that the X
chromosome is in fact more frequently involved in CNVs than other chromosomes for
both primary and secondary CNVs in this cohort. In addition, we also observed that 2
CNVs occur frequently on the same chromosome, and that the increased frequency of YY combination suggest variants are occurring on the same chromosome and not the
homolog. Lastly, we identified that CNVs involving the sex chromosomes appear to
behave differently than those on the autosome in a variety of categories. The
observations of this study are an essential component in better understanding CNV
genesis, and can be applied in the future towards proper counseling when additional
CNVs are identified.
Along with X chromosome, we observed an enrichment of secondary CNVs in
chromosomes 15 and 16. In a study by Girirajan et al. involving a cohort of individuals
with developmental delay, there was a similar enrichment for secondary site variants on
chromosome 16, although this was specific to known microdeletion/duplications
(Girirajan et al. 2012). Here we are working with a larger cohort of affected individuals,
without a specific indication and recognize a similar prevalence of chromosome 16
CNVs, overall, indicating this chromosome is frequently involved in CNVs regardless of
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indication. This is likely due to the high density (8.2% intrachromosomal, 9.2%
interchromosomal) of segmental duplications comprised of this chromosome, making it
more susceptible to homologous recombination errors (Zhang et al. 2005). Similarly,
chromosome 15 has a higher density of intrachromosomal segmental duplications
comparative to others (5.5% intrachromosomal, 7.1% interchromosomal), likely
explaining the higher frequency of CNVs seen on this chromosome (Zhang et al. 2005).
What remains a question is the reason for increased involvement of the X chromosome
in secondary CNVs. In contrast, the X chromosome has a density of approximately 2%
intrachromosomal segmental duplications, and 5% interchromosomal which suggests
that CNV formation by nonhomologous recombination may be the driving factor of
structural change on the X chromosome, compared to autosomes (Zhang et al. 2005).
Of particular interest is the observed relationship between chromosome
combinations of primary and secondary CNVs. This observed trend that the plurality of
individuals have 2 CNVs on the same chromosome, and high frequency of Y-Y,
combination could suggest that both CNVs are occurring on the same chromosome.
Based on this, it is a possibility that CNVs larger than 500 kbp have an inefficiency of
homologous and/or nonhomologous recombination mechanisms and increases the
susceptibility of having an additional CNV on the same chromosome.
CNVs involving the X chromosome have been implicated as a cause of X-linked
ID in males of families who had at least two males affected, with asymptomatic
heterozygous females. (Whibley et al. 2010). In our study, we identified 12 females with
a primary, pathogenic CNV involving the X chromosome, half of whom were described
with some form or ID. We did not account for males in this analysis as an attempt to
control for chromosome size and dosage. However, our results suggest two hypotheses:
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CNVs on the X chromosome can also account for ID in females which may be
exacerbated by skewed x-inactivation, or that females with 2 CNVs, one including the X
chromosome, are at an increased sensitivity to ID when there is an additional CNV
present.
Sex chromosome abnormalities (SCA), with the exception of Turner syndrome,
often go undiagnosed related to a mild presentation. (Christian et al. 2000). However, if
a SCA is suspected, a karyotype would be the most conventional test to order rather than
CMA. In this study we identified 8 individuals with SCA, speculating that a more severe
phenotype presented in these individuals. We can conclude that some individuals had a
phenotype inconsistent with SCA, which strengthens conclusions drawn from previous
research hypothesizing that the addition of CNVs are an independent factor contributing
to intellectual disability and more distinct phenotypes in individuals with SCA and
neurodevelopmental disorders (Le Gall et al. 2017).
Sex chromosome CNVs do behave differently than CNVs on the autosomes in a
few categories. Median sizes of sex chromosome CNVs were smaller than those of
autosomes. Specifically, secondary CNVs on the sex chromosomes are smaller than on
the autosomes. One explanation may be that, given that the Y chromosome is one of the
smallest chromosomes, median sizes are inherently more capable of being larger on
autosomes and may explain the size comparison difference. When comparing variant
classes between sex chromosome and autosome CNVs, we did observe a statistically
significantly difference in variant class for both primary and secondary CNVs
(p<0.001). For both groups of CNVs, we observed a higher proportion of sex
chromosome CNVs to be classified as duplications, while autosomes had a more even
distribution of deletions/duplications. A study by Whibley et al. identified that rare
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CNVs on the X chromosome showed a slightly increased tendency for deletions, with a
greater frequency of deletions found at smaller sizes while duplications dominated larger
sized CNVs (Whibley et al. 2010). Duplications on the X chromosome were seen in
greater frequency both at larger and smaller variants in our study, making us unable to
corroborate this previous study (Whibley et al. 2010). Our study did have a smaller
sample size of X chromosome CNVs as well as a broader phenotypic spectrum of
individuals which may account for the inconsistencies. However, a similar conclusion as
Whitley et al. can be drawn that duplications on the X chromosome may be more
tolerable to human compatibility than deletions. Lastly, when analyzing pathogenicity of
CNVs on sex chromosomes compared to autosomes, a significant difference for both
primary (p<0.001) and secondary CNVs (p<0.001) was observed. In general, CNVs on
the sex chromosomes were less likely to be pathogenic/LP when compared to the
autosomes and more likely to be classified as a VUS. One thought is that the enrichment
of VUS on the X chromosome can be attributed to x inactivation and therefore the
uncertainty of contribution to the phenotype. This observation could also suggest that
pathogenic variants on the sex chromosomes are more deleterious to human life
compared to the autosomes. This analysis reinforces that there is still much to learn
regarding copy variable regions of the sex chromosomes and to what extent they
contribute to phenotype. For future directions, it would be essential to take a closer look
at those individuals with sex chromosome CNVs and characterize their phenotype,
which may lead to identification of copy number variable regions of interest.
We compared combinations of pathogenicity groups and variant classifications
depending on whether a primary CNV fell on an autosome or sex chromosome. For
pathogenicity combinations, regardless of where the primary CNV fell, most individuals
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had two CNVs that were characterized as VUS. This finding may highlight the
complexity that goes into classifying copy number variable regions and that more
research is needed to elucidate pathogenicity and contribution to phenotypes. Next we
looked at combinations of variant classes, again comparing combinations depending on
if the primary CNV fell on a sex chromosome or autosome. We observed that regardless
of where the primary CNV lie, most individuals had a primary CNV considered a gain,
and a secondary CNV that was a loss. This illustrates that the most tolerated
combinations of CNVs are those in which a gain is involved. These two analyses
suggests that in individuals with two CNVs we can predict similar combination of
pathogenicity and variant classes regardless if the primary CNV is on the sex
chromosome or autosomes. .While this analysis of sex chromosome CNVs focused on
females for simplification, it may have missed the true representation of CNVs on the
sex chromosomes, specifically the X chromosome. It is possible that by including males
in this analysis we would have identified more primary, pathogenic CNVs on the X
chromosome, given that males are more commonly affected than females in X-linked
conditions.
We observed a male bias towards multiple CNVs in this study that is worth
acknowledging. It is widely accepted that chromosomal microarray analysis is a fist tier
testing strategy for individuals with unexplained intellectual disability/developmental
delay, autism spectrum disorders (ASD), or multiple congenital anomalies (Miller et al.
2010). Research has shown that there exists a prevalence of males in ASD with a ratio of
4 affected males to 1 affected female (Werling and Geschwind 2013). An explanation
for our finding is due to the increased prevalence of ASD in males, requiring more males
than females to undergo CMA. If this is the case, then our study is not capturing the true
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prevalence of multiple CNVs in females and it cannot be concluded that males are truly
more likely to harbor multiple CNVs.
Our results suggest that CNVs on the sex chromosomes appear to be a common
finding in the clinical setting. It is documented that recurrent de novo and inherited
CNVs located on the sex chromosomes have been implicated in individuals with
disorders of sexual development, dysmorphic features, and neurologic disorders
(Tannour-Louet et al. 2010, Kokalj Vokac et al. 2002, Whibley et al. 2010). However,
given the large proportion of sex chromosome CNVs in this cohort, as well as lack of
definite variant classification, it is possible that sex chromosomes play a larger role in
phenotypic indications than originally thought. It would be important to identify how
and to what extent CNVs on the sex chromosomes impact phenotype as this information
could be imperative for patient management.
To our knowledge, these results are the first of its kind to describe the
involvement of sex chromosomes for multiple CNVs. Strengths of this study include a
large sample size allowing for a more accurate generalization. We identified two small
cohorts (individuals with SCA plus additional CNV and individuals with pathogenic sex
chromosome CNV) of individuals for which phenotypic implications may be drawn and
used clinically. Observations of specific chromosome combinations involved in CNVs
can be used in future studies to identify phenotypic presentations and applied to clinical
settings. We do recognize the limitations in this study as there are no control samples to
compare conclusions to, but it would be difficult to find a set on controls with multiple
CNVs larger than 0.5 Mbp, as pathogenicity increases with increase CNV size.
Limitations secondary to this type of data analysis include no information on the
platform of the microarray used, which may be more or less sensitive to current
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technology. CNVs falling within the pseudoautosomal region (PAR) are often displayed
as a gain or loss on the X chromosome, and FISH technology must be used to determine
which sex chromosome is involved. Without knowing whether or not a confirmatory
analysis was performed, these results may suggest an enrichment on the X chromosome
that is not present. Additionally, we recognized a large number of unknown information
due to lack of submission from the referring center to DECIPHER. For sex chromosome
CNVs, some studies were completed in only females to control for chromosome dosage
and size and the same conclusions may not be applicable to males or all sex
chromosome CNVs. It must be noted that rearrangements with an inverted duplication
contiguous to a distal deletion exist and were not accounted for in this study. Therefore,
enrichment of CNVs on the same chromosome may be present and future studies should
consider removal of these variants, such that these CNVs are related to one another and
generated by the same mechanism (Zuffardi et al. 2009, Bonaglia et al. 2009).
While this analysis is a step towards better understanding the general
characteristics of secondary CNVs and sex chromosomes involvement in CNVs, future
studies are indicated. Additional analysis of CNVs as functions of gene and segmental
duplication densities may elucidate specific chromosome patterns. The inclusion of a
control group for smaller CNVs can further extrapolate if there are certain chromosomes
heavily involved in CNVs of unhealthy vs healthy individuals, perhaps highlighting
unknown regions of importance in the genome. It would also be interesting to compare
similar studies in males vs females investigating if characteristics are similar in both
sexes. In general, future studies identifying patterns of CNV associations is imperative
to better understanding phenotypes which can be used for more accurate counseling and
patient care and to guide variant classification. Multiple studies have identified that the
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addition of CNVs is implicated as a novel disease modifying mechanism (Prakash et al.
2016, Girirajan et al. 2012). Continuing to identify CNV combinations and specific
patterns will highlight important areas of the genome and be key to understanding
complex phenotypes.
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